Please assess the completion status of the following clinical trial:

Trial Title: Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who were randomized into study N01280 \[NCT00419094\], and completed the 2 week up titration period~Exclusion Criteria:~* Subjects who did not meet the inclusion/exclusion criteria for N01280 \[NCT00419094\]~* Subjects who were discontinued prior to the end of titration period

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Keppra XR (Levetiracetam XR) (Type: EXPERIMENTAL): 1000 - 3000 mg/day Keppra XR (Levetiracetam XR), flexible dosing, throughout the duration of the study (planned: approximately 6 months-3 years)

Based on this trial design, predict the completion outcome and termination type (if applicable).